Citius Pharma CEO to present at Jefferies London Healthcare Conference, highlighting LYMPHIR commercialization.

Citius Pharmaceuticals CEO Leonard Mazur will participate in the Jefferies London Healthcare Conference from November 16-19, 2026, to discuss the company's business and recent progress. The company is focusing on the commercialization of LYMPHIR, a targeted immunotherapy launched by its majority-owned subsidiary Citius Oncology for treating certain lymphoma patients. Citius Pharma also has late-stage products like Mino-Lok and Halo-Lido in development, with ongoing FDA engagements for next steps. This event offers investors insight into Citius Pharma's growth and pipeline advancements.

Citius Pharmaceuticals (CTXR) trades at USD 0.49 on Pluang as of Nov 11, 2026, 20:11 WIB, down 1.22% in the last day. The stock's market cap stands at $13.66 million with a 52-week low of $0.37 and high of $1.44. Most Pluang investors hold CTXR for about 19 days, showing active interest in this health sector stock during its development phase.